(Q24241855)

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Risk and prognostic factors in trophoblastic neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Single agent etoposide in gestational trophoblastic tumours. Experience at Charing Cross Hospital 1978-1987.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Workshop Report: Combining the staging system of the International Federation of Gynecology and Obstetrics with the scoring system of the World Heath Organization for Trophoblastic Neoplasia. Report of the Working Committee of the International Soci

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Actinomycin D as the primary agent for gestational trophoblastic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Forty-five year's experience of the treatment of choriocarcinoma and invasive mole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Chemotherapy using 5-fluorouracil and nitrocaphanum in malignant trophoblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Primary oral etoposide therapy in gestational trophoblastic disease. An update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease. A prospective phase II trial of the Gynecologic Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Alternating methotrexate and dactinomycin in nonmetastatic gestational trophoblastic disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

High-Dose Methotrexate for Gestational Trophoblastic Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Treatment of metastatic trophoblastic disease: good and poor prognosis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Treatment of nonmetastatic gestational trophoblastic disease: Results of methotrexate alone versus methotrexate-folinic acid

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Actinomycin D toxicity in the treatment of trophoblastic disease: a comparison of the five-day course to single-dose administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Pulse actinomycin D scheduling in nonmetastatic gestational trophoblastic neoplasia: Cost-effective chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Single-dose actinomycin D in the treatment of postmolar trophoblastic disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Methotrexate with citrovorum factor rescue in gestational trophoblastic disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021

Comparison of chemotherapies with methotrexate, VP-16 and actinomycin-D in low-risk gestational trophoblastic disease. Remission rates and drug toxicities

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007102.PUB2

7 January 2021